781650-33-7Relevant academic research and scientific papers
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: Discovery of N-(3R,6S)-6-(2,3- difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl-4-(2-oxo-2, 3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974)
Paone, Daniel V.,Shaw, Anthony W.,Nguyen, Diem N.,Burgey, Christopher S.,Deng, James Z.,Kane, Stefanie A.,Koblan, Kenneth S.,Salvatore, Christopher A.,Mosser, Scott D.,Johnston, Victor K.,Wong, Bradley K.,Miller-Stein, Cynthia M.,Hershey, James C.,Graham, Samuel L.,Vacca, Joseph P.,Williams, Theresa M.
, p. 5564 - 5567 (2008/03/17)
Calcitonin gene-related peptide (CGRP) has been implicated in the pathogenesis of migraine. Herein we describe optimization of CGRP receptor antagonists based on an earlier lead structure containing a (3R)-amino-(6S)- phenylcaprolactam core. Replacement of the phenylimidazolinone with an azabenzimidazolone gave stable derivatives with lowered serum shifts. Extensive SAR studies of the C-6 aryl moiety revealed the potency-enhancing effect of the 2,3-difluorophenyl group, and trifluoroethylation of the N-1 amide position resulted in improved oral bioavailabilities, ultimately leading to clinical candidate 38 (MK-0974).
Cgrp Receptor Antagonists
-
Page/Page column 37, (2008/06/13)
Compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, D, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or pr
CGRP RECEPTOR ANTAGONISTS
-
Page 100, (2008/06/13)
The present invention is directed to compounds of Formula (I) and Formula (II) (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
